Sarwal Amita* and Bharti Sunil
The aim of the study was to develop a drug delivery system that could improve the therapeutic efficacy and onset of action of Fluoxetine, a commonly used antidepressant. FXT acts by blocking serotonin transport receptors.
Two different methods were used to create mucoadhesive buccal tablets containing fluoxetine hydrochloride. The first method used was the direct compression method, in this method the tablets were prepared by compressing the crystalline ingredients together. The optimized batch (B2) was selected based on the results obtained from various studies conducted. Also, a lyophilized tablet batch (L1) was prepared using the same polymer as in the B2 batch. This was achieved through the solvent casting freeze drying method. Several studies were performed on the developed tablets, including in-vitro and ex-vivo release studies, pre-formulation studies, and characterization of the tablets. Compatibility studies using techniques like DSC (Differential Scanning Calorimetry) and FTIR (Fourier Transform Infrared Spectroscopy) were conducted to ensure that the drug was compatible with the tablet components. Cytotoxicity studies were also carried out using L929 (fibroblast) cells as a cell line model. The results of these various studies were then compared, and it was observed that the lyophilized batch (L1) demonstrated better performance than the directly compressed batch (B2).
Overall, the current work highlights the development and comparison of fluoxetine hydrochloride-containing mucoadhesive buccal tablets using different techniques. The aim was to enhance the effectiveness and convenience of fluoxetine administration, potentially leading to improved patient compliance and faster onset of therapeutic effects in the treatment of depression.
Published Date: 2024-03-06; Received Date: 2024-01-08
